Certara, Inc. (CERT)

Market Cap	2.28B
Revenue (ttm)	385.15M
Net Income (ttm)	-12.05M
Shares Out	161.02M
EPS (ttm)	-0.08
PE Ratio	n/a
Forward PE	31.51
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,114,174
Open	13.61
Previous Close	13.53
Day's Range	13.45 - 14.16
52-Week Range	8.64 - 17.94
Beta	1.64
Analysts	Buy
Price Target	15.00 (+6.01%)
Earnings Date	May 5, 2025

About CERT

Certara, Inc., together with its subsidiaries, provides technology-enabled services and software products for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solutions to predict pharmacokinetics and pharmacodynamics; Simcyp simulator, a mechanistic biosimulation platform for physiologically based pharmacokinetic simulation; Simcyp Discovery for scientists worki...

• Industry: Health Information Services
• Sector: Healthcare
• IPO Date: Dec 11, 2020
• Employees: 1,546
• Stock Exchange: NASDAQ
• Ticker Symbol: CERT
• Website: https://www.certara.com

Financial Performance

In 2024, Certara's revenue was $385.15 million, an increase of 8.70% compared to the previous year's $354.34 million. Losses were -$12.05 million, -78.23% less than in 2023.

Analyst Forecast

According to 6 analysts, the average rating for CERT stock is "Buy." The 12-month stock price forecast is $15.0, which is an increase of 6.01% from the latest price.

Price Target

$15.0

(6.01% upside)

Analyst Consensus: Buy